Please assess the completion status of the following clinical trial:

Trial Title: Study of Antibiotics in the Treatment of Colonic Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are 16 years of age or older.~* Patients who have been diagnosed with Crohn's disease for more than 1 month.~* Patients with CDAI scores between 220 and 450 at the randomization visit.~* Patients with Crohn's disease involving any portion of the colon (more than erythema and/or 10 aphthoid ulcers) with or without distal or terminal ileal disease. (Subjects may have had previous partial colonic resection consisting of less than 50% of the estimated length of the colon.)~Exclusion Criteria:~* Female patients who are, or may become, pregnant during the course of the study or women who are breastfeeding.~* Patients who have an allergy or contraindication to ciprofloxacin or to metronidazole.~* Patients who are experiencing a complication of Crohn's disease (e.g. perforation, acute obstruction, hemorrhage) requiring urgent surgical intervention.~* Patients with subacute small bowel obstruction.~* Patients with significant, symptomatic Crohn's disease of the esophagus, the stomach, the duodenum, or the jejunum.~* Patients who have received, i)any antibiotic within 2 weeks of the screening visit, ii)systemic corticosteroid therapy within 2 weeks of the screening visit, iii)parenteral nutritional therapy within 2 weeks of the screening visit, iv)enteral elemental or polymeric nutritional therapy or exclusively liquid diet within 2 weeks of the screening visit, v) infliximab within 12 weeks of the screening visit, vi)an initiation of therapy with sulphasalazine or with any 5-ASA preparation within 4 weeks of the screening visit or a change in the dose within 2 weeks of the screening visit (Patients on stable doses of sulphasalazine or of a 5-ASA preparation for at least 2 weeks prior to the screening visit are eligible for entry into the study if the total duration of the therapy is at least 4 weeks prior to screening.), vii)an initiation of azathioprine, 6-MP, or methotrexate within 12 weeks of the screening visit or changes in the dose of azathioprine, of 6-MP, or of methotrexate within 4 weeks of screening visit (Patients receiving azathioprine, 6-MP, or methotrexate for at least 12 weeks and at a stable dose for at least 4 weeks prior to the screening visit are eligible for inclusion.), viii)other therapy not listed above for Crohn's disease within 4 weeks of the screening visit, AND/OR ix)any investigational drug within 12 weeks of the screening visit.~* Patients whose stool culture tests positive for enteric pathogens at the screening visit.~* Patients whose stool assay is positive for Clostridium difficile toxin at the screening visit.~* Patients who have another clinically significant medical or psychiatric illness (as judged by the investigator).~* Patients who have had a resection of more than 100 cm of their small intestine, more than half of their colon, or who have an ileostomy.~* Patients who are unable to provide informed consent.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I (Type: PLACEBO_COMPARATOR): Ciprofloxacin placebo and Metronidazole placebo
- II (Type: EXPERIMENTAL): Ciprofloxacin 500 mg bid po Metronidazole - total daily dose dependent on body weight

Based on this trial design, predict the completion outcome and termination type (if applicable).